Newbridge Financial Services Group, Inc. Clovis Oncology, Inc. Transaction History

Newbridge Financial Services Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 13, 2022	SELL	$1.05 - $2.85 $685 - $1,861	-653 Reduced 4.96%	12,500 $15,000
Q2 2022 Jul 15, 2022	BUY	$0.63 - $2.96 $4,095 - $19,240	6,500 Added 97.7%	13,153 $24,000
Q3 2021 Oct 27, 2021	BUY	$4.06 - $5.8 $14,209 - $20,300	3,500 Added 111.01%	6,653 $30,000
Q1 2021 Sep 07, 2021	BUY	$4.81 - $10.34 $7,950 - $17,092	1,653 Added 110.2%	3,153 $22,000
Q3 2020 Sep 07, 2021	BUY	$4.82 - $7.72 $7,230 - $11,580	1,500 New	1,500 $9,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.